ADRX insider trading
NasdaqGS HealthcareADARx Pharmaceuticals, Inc.: insider trade history from SEC Form 4 filings.
About ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer's disease. The company was incorporated in 2019 and is based in San Diego, California.
Company website: www.adarx.com
ADRX insider activity at a glance
FilingIQ tracks 24 insider transactions for ADRX in filings since Sep 29, 2026. The most recent transaction is dated Sep 28, 2026.
Across the full history, 6 open-market purchases
and 0 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ADRX insider trades is 59.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ADRX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for ADRX?
- FilingIQ tracks 24 Form 4 insider transactions for ADRX (ADARx Pharmaceuticals, Inc.), covering filings from Sep 29, 2026 onwards. 24 of those are dated within the last 90 days.
- Are ADRX insiders net buyers or net sellers?
- Across the full Form 4 history for ADRX, 6 transactions (25%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ADRX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is ADRX in?
- ADARx Pharmaceuticals, Inc. (ADRX) is classified in the Healthcare sector, specifically Biotechnology.
Methodology & sources
Every ADRX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.